Objective: Antipsychotic drug efficacy may have decreased over recent decades. The
authors present a meta-analysis of all placebo-controlled trials in patients with acute …

Background Antipsychotic medication reduces the severity of serious mental illness (SMI)
and improves patient outcomes only when medicines were taken as prescribed …

Schizophrenia is the eighth leading cause of disability worldwide in people aged 15–44
years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective …

Antipsychotic polypharmacy in schizophrenia is much debated, since it is common and
costly with unclear evidence for its efficacy and safety. We conducted a systematic literature …

Background Negative symptoms of schizophrenia are associated with adverse clinical
outcomes, but there are few effective treatments. We aimed to assess the effects of …

It is often stated that first-episode patients tend to respond better to antipsychotics than
chronic patients, but the exact numbers and moderators of response in this population are …

Objective An important clinical question is how many patients with acute schizophrenia do
not respond to antipsychotics despite being treated for adequate time and with an effective …

Background: Persistent depressive disorder is prevalent, disabling, and often difficult to treat.
The cognitive-behavioral analysis system of psychotherapy (CBASP) is the only …

Context Electronic durable behavior on the material surface was accompanied by a class of
antipsychotic drugs (APD) to describe the surface modification in the designed adsorption …

It is common experience for practising psychiatrists that individuals with schizophrenia vary
markedly in their symptomatic response to antipsychotic medication. What is not clear …